Form 4: Pliant Therapeutics Director Acquires 53,528 Stock Options

Director Steve E. Krognes acquired 53,528 stock options in Pliant Therapeutics on June 13, 2024, at an exercise price of $13.06.

Summary

• On June 13, 2024, Steve E. Krognes, a director of Pliant Therapeutics, acquired 53,528 stock options.
• The exercise price for these options is $13.06.
• The options vest monthly, with 1/36th of the shares becoming exercisable on each monthly anniversary of June 13, 2024, contingent upon continuous service to the Issuer.
• The expiration date for these options is June 13, 2034.
• Following the transaction, Krognes directly owns 53,528 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this is a routine grant.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's increased stake in the company.

Key Dates